Clinical Trial: Cholestasis in Extreme Low Birth Weight Infants (ELBW)
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Cholestasis in Extreme Low Birth Weight Infants (ELBW) - Possible Influences of a Change in Nutrition Policy
Brief Summary:
Parenteral nutrition associated liver disease (PNALD) in preterm neonates is characterized by early occurrence of intrahepatic cholestasis (parenteral nutrition associated cholestasis (PNAC).
Extreme low birth weight infants (ELBW, birth weight < 1000 g) are at increased risk for development of PNAC.
Important factors implicated in the aetiology of PNAC are high caloric parenteral nutrition using amino acids or dextrose, but also intravenous lipids and infections in particular necrotizing enterocolitis (NEC).
Due to a change of paradigm a more aggressive nutrition with early use of parenteral amino acids/lipids and early fortification of mothers milk or alternatively high caloric preterm formula is warranted. Accordingly - in line with the existing expert opinion and evidence - the feeding policy at the neonatal care units of our hospital was adapted.
Evidence exists that PNAC might be caused by the use of high concentrations of amino acids and lipids in parenteral nutrition. Furthermore NEC is associated with high osmotic feeds. Therefore the incidence of PNAC might be increased directly and indirectly after introducing the new feeding policy.
The investigators therefore aim at retrospectively investigating the incidence of PNAC before and after introduction of a feeding policy of "aggressive nutrition" for ELBW infants.
Detailed Summary:
Sponsor: Medical University of Vienna
Current Primary Outcome: Cholestasis [ Time Frame: Assessment of bilirubin levels at least every second week from birth (0 weeks) to discharge (i.e. up to an average of 12 weeks) ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Growth [ Time Frame: At study entry (after birth, 0 weeks) and discharge (i.e. at an average of 12 weeks) ]
Original Secondary Outcome: Same as current
Information By: Medical University of Vienna
Dates:
Date Received: July 12, 2010
Date Started: January 2010
Date Completion:
Last Updated: September 30, 2016
Last Verified: September 2016